Agent for gene transfer

• US 7,462,703 B2
• Filed: 01/31/2003
• Issued: 12/09/2008
• Est. Priority Date: 01/31/2003
• Status: Expired due to Fees

• Current Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin
• Original Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin
• Inventors: Reszka, Regina, Berndt, Antje
• Primary Examiner(s): VIVLEMORE, TRACY ANN
• Application Number:
  US10/355,933
• Publication Number:
  US 20040152647A1
• Time in Patent Office: 2,139 Days
• Field of Search: 536/23.1, 536/24.5
• US Class Current: 536/23.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/0025 wherein the non-active part clearly interacts with the delivered nucleic acid
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

An agent for the transfer of genetic material comprising a genetic material, PEG-containing liposomes, one or more additional polymer particles and a contrasting agent. The invention also is directed toward methods of preparing the agent, and methods of using the agent to affect gene transfer.

Claims

1. A composition suitable for effecting gene transfer, consisting of:

(a) one or more genetic materials chosen from the group consisting of DNA and RNA,

(b) liposomes consisting of (1) PEG, (2) a steroid, (3) a charged lipid component, (4) genetic material and (5) a carrier liquid,

(c) one or more polymer particles selected from the group consisting of nanoparticles, starch particles, gelatin, and Poloxamer,

(d) contrasting agent selected from the group consisting of iodine-, gadolinium-, magnetite- and fluorine-containing contrasting agent, and

(e) at least one component that assists in packing DNA more tightly.

2. The composition of claim 1, wherein the component that assists in packing DNA more tightly is selected from the group consisting of nuclear capsid protein NCP 7, HMG, polyethylene imine, poly-L-lysine and protamine sulfate.

3. The composition of claim 1, wherein the genetic material encodes one or more proteins selected from the group consisting of herpes simplex-virus thymidine kinase gene (HSVtk), deaminase, NR/CB 1954, purine nucleoside phosphorylase and cytokine genes.

4. The composition of claim 1, wherein the genetic material encodes at least one interleukin (IL) selected from the group consisting of IL-2, IL-4, IL-6, IL-10, L-12 and IL-15.

5. The composition of claim 1, wherein the molar ratio of amphiphile to steroid to charged lipid component is 1:

0.3;

0.1.

6. The composition of claim 1, wherein the molar ratio of amphiphile to steroid to charged lipid component is 1:

1;

0.1.

7. The composition of claim 1, wherein the molar ratio of amphiphile to steroid to charged lipid component is or 1:

1;

0.5.

8. The composition of claim 1, wherein the molar ratio of charged lipid component to contrasting agent is from 2:

1 to 10;

1.

9. The composition of claim 1, wherein the steroid is chosen from the group consisting of cholesterol, diethoxycholesterol and sitosterol.

10. The composition of claim 1, wherein the charged lipid component is an anion of a lipid selected from the group consisting of diacetyl phosphate, palmitic acid, stearic acid, a phospholipid, and a sphingolipid.

11. The composition of claim 10, wherein the charged lipid component is fluorinated.

12. The composition of claim 1, wherein the polymer particles consist of a 25% aqueous solution of Poloxamer.

13. The composition of claim 1, wherein the liposomes are present in at least one form selected from the group consisting of SUV (small unilamellar vesicles), LUV (large unilamellar vesicles), REV (reverse phase evaporation vesicles), MLV (multilamellar vesicles), and 3β

N-(N,N′

-dimethylaminoethane)-carbamoyl cholesterol (DAC-chol) liposomes.

14. The composition of claim 1, wherein the polymer particles consist of starch particles having an average diameter of 40 μ

m to 90 μ

m.

15. The composition of claim 14, wherein the starch particles have a particle size of 60 μ

m to 90 μ

m.

16. The composition of claim 14, wherein the starch particles have a concentration of from 5 mg/ml to 70 mg/ml upon resuspending the composition in water or aqueous buffer.

17. The composition of claim 1, wherein the polymer particles consist of gelatin.

18. The composition of claim 1, wherein the contrasting agent consist of phenyl derivatives having one or more iodine substituents.

19. The composition of claim 18, wherein the contrasting agent is selected from the group consisting of Iopromide, Ioxitalamate, Ioxagate, Iopamidol, Iohexyl, Iotralon, and Metrizamide.

20. The composition of claim 1, wherein the fluorine-containing contrasting agents consist of fluorinated lipids.

21. The composition of claim 1, consisting of

(a) a LacZ gene and a HSVtk gene,

(b) MLV PEG liposomes,

(c) starch particles and

(d) the contrasting composition is fluorinated.

22. The composition of claim 1, wherein the genetic material is encapsulated in MLV PEG, and the polymer particles are starch particles.

23. The composition of claim 1, wherein the polymer particles are lyophilized starch particles.

24. The composition of claim 1, wherein the polymer particles are degradable starch particles.

25. The composition of claim 1, comprising 30 mg to 90 mg of starch particles and 5 mg to 100 mg of genetic material.

26. The composition of claim 1, wherein the polymer particles are nanoparticles.

27. The composition of claim 10, wherein the phospholipid is chosen from the group consisting of phosphatidyl serine and phosphatid acid;

the sphingolipid is sulfatide; and

the PEG is MPEG.

28. A composition suitable for effective gene transfer consisting of:

(a) one or more genetic materials chosen from the group consisting of DNA and RNA;

(b) liposomes consisting of (1) PEG, (2) steroid, (3) a charged lipid component, (4) genetic material, and (5) a carrier liquid;

(c) one or more polymer particles selected from the group consisting of nanoparticles, starch particles, gelatin and Poloxamer;

(d) a contrasting agent selected from the group consisting of iodine-, gadolinium-, magnetite-, and fluorine-containing contrasting agents;

(e) at least one component that assists in packing DNA more tightly; and

(f) anti-Ki-67-immune PEG liposomes or anti-CEA PEG liposomes,

wherein the liposomes are present in at least one form selected from the group consisting of small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), reverse phase evaporation vesicles (REV, mulitlumellar vesicles (MLV) and 3β

N-(N,N′

-dimethylaminoethane)-carbamoyl cholesterol (DAC-chol) liposomes.